Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 920 mg solution for injection
MN45053
Phase 3 small_molecule active
Quick answer
Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 920 mg solution for injection for Multiple Sclerosis is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Multiple Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active